PL2139515T5 - Atenuowane wirusy przydatne w szczepionkach - Google Patents
Atenuowane wirusy przydatne w szczepionkachInfo
- Publication number
- PL2139515T5 PL2139515T5 PL08799746.6T PL08799746T PL2139515T5 PL 2139515 T5 PL2139515 T5 PL 2139515T5 PL 08799746 T PL08799746 T PL 08799746T PL 2139515 T5 PL2139515 T5 PL 2139515T5
- Authority
- PL
- Poland
- Prior art keywords
- vaccines
- attenuated viruses
- viruses useful
- useful
- attenuated
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
- 230000002238 attenuated effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12361—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32661—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32661—Methods of inactivation or attenuation
- C12N2770/32662—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32671—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32761—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32761—Methods of inactivation or attenuation
- C12N2770/32762—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90938907P | 2007-03-30 | 2007-03-30 | |
US6866608P | 2008-03-07 | 2008-03-07 | |
EP08799746.6A EP2139515B2 (en) | 2007-03-30 | 2008-03-31 | Attenuated viruses useful for vaccines |
PCT/US2008/058952 WO2008121992A2 (en) | 2007-03-30 | 2008-03-31 | Attenuated viruses useful for vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
PL2139515T3 PL2139515T3 (pl) | 2018-11-30 |
PL2139515T5 true PL2139515T5 (pl) | 2024-04-08 |
Family
ID=39808891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL08799746.6T PL2139515T5 (pl) | 2007-03-30 | 2008-03-31 | Atenuowane wirusy przydatne w szczepionkach |
Country Status (13)
Country | Link |
---|---|
US (4) | US9476032B2 (pl) |
EP (3) | EP3431099B1 (pl) |
JP (2) | JP5733976B2 (pl) |
KR (1) | KR101621100B1 (pl) |
CN (1) | CN103476425B (pl) |
AU (1) | AU2008232491B2 (pl) |
BR (1) | BRPI0809600B1 (pl) |
CA (1) | CA2682089C (pl) |
DK (1) | DK2139515T4 (pl) |
HR (1) | HRP20181319T4 (pl) |
MX (2) | MX349825B (pl) |
PL (1) | PL2139515T5 (pl) |
WO (1) | WO2008121992A2 (pl) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0809600B1 (pt) * | 2007-03-30 | 2023-01-24 | The Research Foundation Of State University Of New York | Vírus atenuado útil para vacinas |
WO2010039649A2 (en) * | 2008-10-03 | 2010-04-08 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Flavivirus-based system for production of hepatitis c virus (hcv) |
EP2391713A1 (en) | 2009-01-30 | 2011-12-07 | The Board Of Regents For Oklahoma State University | Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs |
EP2403527A4 (en) * | 2009-03-06 | 2012-11-14 | Sinai School Medicine | LIVELY WEAKED INFLUENZA VIRUS VACCINES WITH MICRORNA REACTION ELEMENTS |
WO2011044561A1 (en) * | 2009-10-09 | 2011-04-14 | The Research Foundation Of State University Of New York | Attenuated influenza viruses and vaccines |
EP2490268A1 (en) * | 2011-02-03 | 2012-08-22 | Imec | Method for fabricating photovoltaic cells |
EP2751260A2 (en) * | 2011-09-02 | 2014-07-09 | Westfälische Wilhelms-Universität Münster | Live attenuated influenza virus |
CN104204196A (zh) * | 2011-12-16 | 2014-12-10 | 纽约州州立大学研究基金会 | 新型减毒脊髓灰质炎病毒:PV-1单-cre-X |
US20140363469A1 (en) * | 2012-01-19 | 2014-12-11 | Alnylam Pharmaceuticals, Inc. | Viral attenuation and vaccine production |
EP4190895A1 (en) * | 2013-02-08 | 2023-06-07 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization |
CN105189756B (zh) * | 2013-03-14 | 2021-06-11 | 爱默蕾大学 | 具有沉默突变的重组rsv、其相关疫苗和方法 |
DK2969005T3 (da) * | 2013-03-15 | 2020-01-20 | The Resaerch Foundation For The State Univ Of New York | Attenuerede influenzavira og -vacciner |
CN104056276B (zh) * | 2013-03-20 | 2017-05-10 | 上海生物制品研究所有限责任公司 | 一种流感病毒减毒活疫苗及其制备方法 |
CN104419687B (zh) * | 2013-09-03 | 2017-03-15 | 中国农业大学 | 重组PRRS病毒HV‑nsp29及其应用 |
US10400220B2 (en) | 2014-09-05 | 2019-09-03 | The Research Foundation For The State University Of New York | Attenuated virus having multiple hosts |
US10731227B2 (en) | 2014-12-12 | 2020-08-04 | The Trustees Of The University Of Pennsylvania | Compositions, kits, and methods to detect HIV virus |
WO2017099801A1 (en) * | 2015-12-11 | 2017-06-15 | The Trustees Of The University Of Pennsylvania | Compositions, kits, and methods to detect hiv virus |
EP3050962A1 (en) | 2015-01-28 | 2016-08-03 | Institut Pasteur | RNA virus attenuation by alteration of mutational robustness and sequence space |
EP3303571A4 (en) * | 2015-06-04 | 2018-10-17 | The University of Hong Kong | Live-attenuated virus and methods of production and use |
EP3355899A4 (en) * | 2015-09-30 | 2019-04-03 | Ramot at Tel-Aviv University Ltd. | In place of EVOLUTIONARY PRESERVED RNA STRUCTURE MUTATED APPROVED VIRUS |
US11235050B2 (en) | 2015-10-29 | 2022-02-01 | Emory University | Chimeric RSV, immunogenic compositions, and methods of use |
CN105821009B (zh) * | 2016-04-05 | 2019-07-26 | 中国人民解放军第三〇二医院 | 靶向肝癌溶瘤流感病毒的构建及其应用 |
EP3472319B1 (en) | 2016-06-15 | 2024-03-27 | President and Fellows of Harvard College | Methods for rule-based genome design |
EP3488239A1 (en) * | 2016-07-22 | 2019-05-29 | Verily Life Sciences LLC | Quantitative massively parallel proteomics |
US11149255B2 (en) * | 2016-09-06 | 2021-10-19 | Bioventures, Llc | Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors |
CN106650307B (zh) * | 2016-09-21 | 2019-04-05 | 武汉伯远生物科技有限公司 | 一种基于密码子对使用频度的基因密码子优化方法 |
WO2018057950A1 (en) | 2016-09-23 | 2018-03-29 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes |
CN106520832B (zh) * | 2016-11-17 | 2020-02-18 | 新乡医学院 | 双顺反子表达载体、表达系统、制备方法及应用 |
EA201991319A1 (ru) * | 2016-11-30 | 2019-11-29 | Вакцины аттенуированного свиного гриппа и способы их изготовления и применения | |
AR111770A1 (es) | 2017-05-05 | 2019-08-21 | Elanco Us Inc | Vacuna para enfermedad respiratoria bovina |
JP2020530765A (ja) * | 2017-07-17 | 2020-10-29 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | リサウイルス抗原構築物 |
CN111511397A (zh) * | 2017-12-22 | 2020-08-07 | 科达金尼克斯有限公司 | 具有密码子对去优化区域的重组病毒及其用于治疗癌症的用途 |
CN108586608A (zh) * | 2018-04-13 | 2018-09-28 | 四川农业大学 | 一种dhav-1 2c蛋白多克隆抗体、重组融合蛋白及其制备方法 |
CN109504662B (zh) * | 2018-11-09 | 2022-06-10 | 浙江天元生物药业有限公司 | 一种柯萨奇病毒减毒株及其应用 |
CA3121430A1 (en) | 2018-12-14 | 2020-06-18 | Glaxosmithkline Biologicals Sa | Heterologous prime boost vaccine compositions and methods |
EP4096712A4 (en) * | 2020-01-28 | 2024-05-08 | Codagenix Inc. | DE-OPTIMIZED SARS-COV-2 AND METHODS OF USE |
CN111321125B (zh) * | 2020-02-03 | 2022-07-19 | 广州医科大学 | 重组流感病毒及其在疫苗中的应用 |
CN111269895B (zh) * | 2020-02-03 | 2022-09-27 | 广州医科大学 | 甲型流感病毒减毒株及其作为骨架病毒和疫苗的应用 |
WO2021191342A1 (de) * | 2020-03-27 | 2021-09-30 | Reinmueller Johannes | Virustatisches mittel |
CN111481663B (zh) * | 2020-04-09 | 2022-12-09 | 广州医科大学 | 一种流感病毒活疫苗及其制备方法 |
US20230143228A1 (en) * | 2020-04-21 | 2023-05-11 | Emory University | Coronavirus vaccines, compositions, and methods related thereto |
PE20230833A1 (es) * | 2020-05-27 | 2023-05-19 | Us Agriculture | Cepas vivas atenuadas de la fiebre aftosa modificadas por desoptimizacion y usos de estas |
EP4179074A1 (en) * | 2020-07-07 | 2023-05-17 | Codagenix Inc. | Method of producing modified virus genomes and producing modified viruses |
EP4181956A1 (en) * | 2020-07-16 | 2023-05-24 | Griffith University | Live-attenuated virus vaccine |
US20240018609A1 (en) * | 2020-08-19 | 2024-01-18 | City Of Hope | Lamp detection of sars-cov-2 in saliva for the rapid diagnosis of covid-19 |
CN112662633A (zh) * | 2020-12-28 | 2021-04-16 | 中国水产科学研究院珠江水产研究所 | II型草鱼呼肠孤病毒冷适应株GCRV-GD108ca及其应用 |
CA3223318A1 (en) * | 2021-06-23 | 2022-12-29 | Muhammad Munir | Virus attenuation |
US20230274791A1 (en) * | 2021-11-29 | 2023-08-31 | The Chinese University Of Hong Kong | Codon de-optimization or optimization using genetic architecture |
WO2024036331A2 (en) * | 2022-08-12 | 2024-02-15 | Fred Hutchinson Cancer Center | Barcoded influenza viruses and mutational scanning libraries including the same |
CN117153270B (zh) * | 2023-10-30 | 2024-02-02 | 吉林华瑞基因科技有限公司 | 一种基因二代测序数据处理方法 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6829494A (en) | 1993-08-02 | 1995-02-28 | Chiron Corporation | Recombinant constructs using replacement sequences in hypervariable regions |
US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
US6352842B1 (en) | 1995-12-07 | 2002-03-05 | Diversa Corporation | Exonucease-mediated gene assembly in directed evolution |
US6238884B1 (en) | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
US20040023327A1 (en) | 1995-12-07 | 2004-02-05 | Short Jay M. | End selection in directed evolution |
US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
US6562594B1 (en) | 1999-09-29 | 2003-05-13 | Diversa Corporation | Saturation mutagenesis in directed evolution |
US6764835B2 (en) | 1995-12-07 | 2004-07-20 | Diversa Corporation | Saturation mutageneis in directed evolution |
EP2112220A3 (en) | 1996-07-15 | 2010-01-06 | The Government of the United States of America, as represented by The Department of Health and Human Services | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
GB9705669D0 (en) † | 1997-03-19 | 1997-05-07 | British Tech Group | Attenuated polioviruses |
US6410023B1 (en) | 1997-05-23 | 2002-06-25 | United States Of America | Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene |
EP0966538A1 (en) * | 1997-08-07 | 1999-12-29 | Altwell Biotech. Inc. | Replication-competent recombinant sabin type 1 strain of poliovirus |
EP1690868A1 (en) | 1997-10-31 | 2006-08-16 | Maxygen, Inc. | Modification of virus tropism and host range by viral genome shuffling |
GB9817082D0 (en) † | 1998-08-06 | 1998-10-07 | Btg Int Ltd | Attenuated poliovirus vaccine |
AU1199000A (en) | 1998-09-29 | 2000-04-17 | Maxygen, Inc. | Shuffling of codon altered genes |
CA2361927A1 (en) | 1999-03-09 | 2000-09-14 | Diversa Corporation | End selection in directed evolution |
AU4039400A (en) | 1999-03-26 | 2000-10-16 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
CA2291367A1 (en) * | 1999-12-06 | 2001-06-06 | Isabelle Henry | Genetic constructions having a reduced or an increased number of epigenetic control regions and methods of use thereof |
US20020076415A1 (en) | 1999-12-14 | 2002-06-20 | Jing-Hsiung Ou | Hepatitis C virus gene products |
AUPQ776100A0 (en) | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
GB0017990D0 (en) | 2000-07-21 | 2000-09-13 | Glaxo Group Ltd | Papilloma virus sequences |
WO2002008435A1 (en) | 2000-07-21 | 2002-01-31 | Glaxo Group Limited | Codon-optimized papilloma virus sequences |
IL155154A0 (en) | 2000-09-30 | 2003-10-31 | Diversa Corp | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating |
ATE403152T1 (de) | 2000-10-17 | 2008-08-15 | Besst Test Aps | Test zum direkten nachweisen einer biologischen zelle in einer körperflüssigkeitsprobe |
US20030041354A1 (en) | 2000-10-17 | 2003-02-27 | Novozymes A/S | Transgenic plants |
AU2002326303A1 (en) * | 2001-05-25 | 2002-12-03 | Tao Biosciences, Llc | Methods for attenuation of virulence in bacteria |
ATE471335T1 (de) * | 2002-12-23 | 2010-07-15 | Vical Inc | Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden |
CA2517394A1 (en) | 2003-02-28 | 2005-02-17 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Recombinant human metapneumovirus and its use |
WO2005024012A1 (en) | 2003-09-11 | 2005-03-17 | Novozymes A/S | Increased expression of a modified polypeptide |
EP1735451B1 (en) | 2004-04-07 | 2009-10-28 | Novozymes A/S | Mutated prokaryotic cells with high secretion-levels |
EP2644696B1 (en) | 2004-05-24 | 2015-07-15 | MedImmune, LLC | Method of increasing replication of a reassortant influenza virus in eggs. |
JP2008504839A (ja) | 2004-07-02 | 2008-02-21 | ヘンリー, エル. ニーマン, | コピーチョイス組換え及びその使用法 |
EP1781785B1 (en) | 2004-07-20 | 2010-11-10 | Novozymes, Inc. | Methods of producing mutant polynucleotides |
EP1773995B1 (en) | 2004-08-03 | 2009-10-07 | The Regents Of The University Of California | Site specific system for generating diversity protein sequences |
DK3312272T3 (da) * | 2004-10-08 | 2019-12-02 | Us Gov Health & Human Services | Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner |
US8168771B2 (en) | 2005-01-31 | 2012-05-01 | The Johns Hopkins University | Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
AU2006304268B2 (en) | 2005-10-14 | 2011-09-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Rabies virus vector systems and compositions and methods thereof |
CN106148288A (zh) | 2006-08-25 | 2016-11-23 | 美国国有健康与人类服务部(马里兰州) | 重组修饰的安卡拉痘苗病毒及其应用、质粒载体及其应用 |
US8216844B2 (en) | 2006-08-29 | 2012-07-10 | Danisco Us Inc. | Compositions and methods for improved protein production |
WO2008049782A1 (en) | 2006-10-24 | 2008-05-02 | Basf Se | Method of increasing gene expression using modified codon usage |
PL2082045T3 (pl) | 2006-10-24 | 2015-07-31 | Basf Se | Sposób zmniejszania ekspresji genów poprzez modyfikację częstości występowania kodonów |
US8298541B2 (en) | 2007-03-29 | 2012-10-30 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Live attenuated virus vaccines for La Crosse virus and other Bunyaviridae |
BRPI0809600B1 (pt) | 2007-03-30 | 2023-01-24 | The Research Foundation Of State University Of New York | Vírus atenuado útil para vacinas |
WO2009049351A1 (en) | 2007-10-15 | 2009-04-23 | The University Of Queensland | Construct system and uses therefor |
EP3355899A4 (en) | 2015-09-30 | 2019-04-03 | Ramot at Tel-Aviv University Ltd. | In place of EVOLUTIONARY PRESERVED RNA STRUCTURE MUTATED APPROVED VIRUS |
JP7250520B2 (ja) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 組換えアルテリウイルスレプリコン系およびその使用 |
US11821111B2 (en) | 2019-11-15 | 2023-11-21 | Fred Hutchinson Cancer Center | Barcoded influenza viruses and deep mutational scanning libraries including the same |
-
2008
- 2008-03-31 BR BRPI0809600-7A patent/BRPI0809600B1/pt active IP Right Grant
- 2008-03-31 HR HRP20181319TT patent/HRP20181319T4/hr unknown
- 2008-03-31 KR KR1020097022782A patent/KR101621100B1/ko active IP Right Grant
- 2008-03-31 MX MX2014010788A patent/MX349825B/es unknown
- 2008-03-31 PL PL08799746.6T patent/PL2139515T5/pl unknown
- 2008-03-31 US US12/594,173 patent/US9476032B2/en active Active
- 2008-03-31 WO PCT/US2008/058952 patent/WO2008121992A2/en active Search and Examination
- 2008-03-31 CN CN200880018001.1A patent/CN103476425B/zh active Active
- 2008-03-31 DK DK08799746.6T patent/DK2139515T4/da active
- 2008-03-31 JP JP2010501289A patent/JP5733976B2/ja active Active
- 2008-03-31 EP EP18177156.9A patent/EP3431099B1/en active Active
- 2008-03-31 EP EP23219605.5A patent/EP4368202A2/en active Pending
- 2008-03-31 MX MX2009010549A patent/MX2009010549A/es active IP Right Grant
- 2008-03-31 EP EP08799746.6A patent/EP2139515B2/en active Active
- 2008-03-31 CA CA2682089A patent/CA2682089C/en active Active
- 2008-03-31 AU AU2008232491A patent/AU2008232491B2/en active Active
-
2014
- 2014-12-19 JP JP2014257141A patent/JP2015091247A/ja active Pending
-
2016
- 2016-09-07 US US15/258,584 patent/US10023845B2/en active Active
-
2018
- 2018-07-16 US US16/036,348 patent/US11162080B2/en active Active
-
2021
- 2021-10-28 US US17/513,032 patent/US20220298492A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2139515A4 (en) | WAXED VIRUSES SUITABLE FOR VACCINES | |
GB0822068D0 (en) | Methods for virus design | |
EP2062246A4 (en) | CHIMERIC VIRAL VACCINES | |
GB0807424D0 (en) | Virus | |
ZA201101481B (en) | Vaccine | |
IL208660A0 (en) | Coccididosis vaccines | |
HRP20151124T1 (en) | Vaccine | |
GB0714578D0 (en) | Viruses | |
ZA201001029B (en) | Vaccines | |
GB0822001D0 (en) | Vaccine | |
GB0700135D0 (en) | Vaccine | |
GB0810710D0 (en) | Vaccine | |
ZA201007402B (en) | Vaccine | |
GB0816284D0 (en) | Vaccine | |
GB0816447D0 (en) | Vaccine | |
GB0710538D0 (en) | Vaccine | |
GB0801326D0 (en) | Vaccines | |
GB0823560D0 (en) | Virus | |
GB0709373D0 (en) | BCG-based anti-atheroma vaccine | |
GB0813823D0 (en) | Virus | |
GB0810378D0 (en) | Virus | |
GB0703066D0 (en) | Viruses | |
GB0818459D0 (en) | Vaccines | |
AP2010005295A0 (en) | Vaccine | |
GB0809781D0 (en) | Vaccine |